Description

AbbVie Inc. is a global biopharmaceutical enterprise focused on the discovery, development, production, and worldwide commercialization of pharmaceutical remedies. Its diverse product portfolio targets a wide range of health conditions. Key offerings include HUMIRA, an injectable treatment for autoimmune and intestinal Behçet's diseases; SKYRIZI, indicated for moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor utilized in adults with moderate to severe active rheumatoid arthritis. In oncology, AbbVie provides IMBRUVICA for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), as well as VENCLEXTA, a BCL-2 inhibitor also for adults with CLL or SLL. The company additionally markets MAVYRET for chronic HCV genotype 1-6 infection. Other significant pharmaceutical products encompass CREON, an enzyme therapy addressing exocrine pancreatic insufficiency; Synthroid, prescribed for hypothyroidism; Linzess/Constella, which manages irritable bowel syndrome with constipation and chronic idiopathic constipation; and Lupron, used for the palliative treatment of advanced prostate cancer, endometriosis, central precocious puberty, and anemia stemming from uterine fibroids. Botox therapeutic also forms part of its offerings. In women's health, ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist, alleviates moderate to severe endometriosis pain. For neurological disorders, AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy for adult migraine treatment, with or without aura. Its comprehensive eye care segment includes Lumigan/Ganfort, a bimatoprost ophthalmic solution for lowering elevated intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension; Alphagan/Combigan, an alpha-adrenergic receptor agonist also for IOP reduction in OAG; and Restasis, a calcineurin inhibitor immunosuppressant designed to enhance tear production, alongside other specialized ophthalmic solutions. AbbVie Inc. collaborates on research with Dragonfly Therapeutics, Inc. Established in 2012, the company's headquarters are situated in North Chicago, Illinois.